LYEL
LYEL
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$50.00M
Insider Sales
0
$0
Total Volume
$50.00M
2 transactions
Net Activity
+$50.00M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Arch Venture Partners Ix, LLC
10%
$25.00M total
Arch Venture Fund Xiii, L.P.
10%
$25.00M total
Quick Actions
LYEL has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%. LYEL ranks #37 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at LYEL (LYEL) engaged in a total of 2 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 0 were sales. The total volume of insider trading reached $50.00M.
The net insider activity for LYEL shows a net buying bias of $50.00M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Arch Venture Partners Ix, LLC (10%), who traded 2.32M shares valued at $25.00M on Nov 4, 2026.
Lyell Immunopharma, Inc. (LYEL) Stock Price, News, Quote & History
Lyell Immunopharma Stock Price Forecast. Should You Buy LYEL?
Lyell Immunopharma, Inc. (LYEL) stock price, news, quote and history
LYEL - Lyell Immunopharma Inc Stock Price and Quote
(LYEL) Risk Channels and Responsive Allocation
An approximately $80 million stock sale is expected to help fund Lyell's cancer trials into 2028.
FAQs About LYEL Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for LYEL.